QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clay, P. G Articles by Antoniou, T. Search for Related Content PubMed PubMed Citation Articles by Clay, P. G Articles by Antoniou, T.

HIV-AIDS

Advances in Human Immunodeficiency Virus Therapeutics

Director, Dybedal Clinical Research Center; Associate Professor, Kansas City University of Medicine and Biosciences, Kansas City, MO

Betty J Dong, PharmD

Professor of Clinical Pharmacy, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA

Suellyn J Sorensen, PharmD BCPS

Clinical Pharmacist, Infectious Diseases; Clinical Pharmacy Manager, Indiana University Hospital, Indianapolis, IN

Alice Tseng, PharmD FCSHP

HIV Pharmacotherapy Specialist, Toronto General Hospital; Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

Frank Romanelli, PharmD BCPS

Associate Professor of Pharmacy, College of Pharmacy and College of Health Sciences, University of Kentucky, Lexington, KY

Tony Antoniou, PharmD

Clinical Pharmacy Specialist, Department of Family and Community Medicine, St. Michael's Hospital, Toronto

Reprints: Dr. Clay, Kansas City University of Medicine and Biosciences, 1750 Independence Ave., Kansas City, MO 64106-1453, fax 816/283-2376, pclay{at}kcumb.edu

Abstract

OBJECTIVE: To review recent advances in the management of persons infected with HIV.

DATA SOURCES: A MEDLINE search (March 2003-February 2006) was done to identify recent articles on antiretroviral therapy research, adverse effects, and investigational products. Abstracts and programs of major HIV conferences, held from January 2003 to June 2005, were also reviewed for relevant material.

STUDY SELECTION AND DATA EXTRACTION: Studies and observations conducted with either recently approved or investigational products were selected for inclusion, with conference abstracts primarily used. Excluded were topics covered in recent publications in The Annals.

DATA SYNTHESIS: New modalities for treating HIV, including the CXCR4 and CCR5 receptor inhibitors, have so far shown promise in trial. Tipranavir, a recently approved protease inhibitor, has been shown to be effective in highly resistant patients, but may be unable to be combined with other protease inhibitors. Once-daily emtricitabine and tenofovir have shown superiority compared with lamivudine and zidovudine as backbone nucleoside analogs for combination antiretroviral therapy. Pharmacokinetic considerations for age, gender, race, and which agents are being discontinued have emerged.

CONCLUSIONS: Much progress has been made in the treatment of HIV infection. Tolerability and adherence remain major obstacles to optimizing regimen longevity.

Key Words: adherence, antiretrovirals, HIV, toxicity

Published Online, March 21, 2006. www.theannals.com, DOI 10.1345/aph.1G423

This article has been cited by other articles:

				M. B. Loughrey, P. M. Waring, A. Dobrovic, G. Demetri, S. Kovalenko, and G. McArthur Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin. Cancer Res., October 15, 2006; 12(20): 6205 - 6206. [Full Text] [PDF]